Noxopharm's Sofra assets to be presented at global conference
Key points
- Project with Australian biotechnology leader
- Delivery of self-amplifying mRNA vaccines
- Demonstrates Sofra versatility and industry interest
Full summary
Noxopharm Limited (ASX:NOX) is pleased to announce that data from a project involving Noxopharm's Sofra technology platform will be presented by CSL, a global biopharma company, at the Options for the Control of Influenza XIII Conference in Washington DC. The presentation will highlight how Noxopharm's novel oligonucleotides from its Sofra technology platform could be used to improve the delivery of self-amplifying mRNA vaccines. The Sofra platform, developed from a breakthrough discovery in the immune system, targets inflammatory and autoimmune diseases, as well as RNA therapeutics and vaccines, with potential applications across a wide range of immune-related conditions.
Outlook
Noxopharm CEO Dr Olivier Laczka expressed optimism about the Sofra platform's potential in various areas where inflammation plays a role.
Summary generated by a large language model. Please interpret with care.